Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Aimmune.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

Best Practice™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut Allergy

Best Practice™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut Allergy


Best Practice™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut Allergy

In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com or call (609) 325-4668

Overview:

This activity will address unmet needs in the management of peanut allergy, including understanding the physical and psychosocial burden of the disease, updated clinical guidelines, and new and emerging OIT options. The importance of a multidisciplinary approach to patient-centered care will also be addressed.

Target Audience

These educational activities are primarily directed toward allergists, immunologists, primary care, pediatricians, and clinicians who treat patients with peanut allergy.

Learning Objectives

Upon completion of this activity, learners should be able to:

  1. DISCUSS the physical and psychosocial burdens of peanut allergy and its impact on patients and caregivers.
  2. EXPLAIN the new guideline recommendations regarding early introduction of peanuts.
  3. REVIEW current data on novel immunologic treatments currently in development for peanut allergy, in addition to trial methodologies important to understanding these data.
  4. APPLY collaborative, multidisciplinary care strategies for improving therapeutic management in patients with peanut allergy and their caregivers.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Aimmune.







Become a Member

Forgot Password?
Filter By